Skip to main content
. 2017 Apr 13;9(5):801–811. doi: 10.1080/19420862.2017.1316914

Figure 4.

Figure 4.

Native MS and IM-MS for benchmarking bioconjugation strategies. (a-c) Deconvoluted native mass spectra from the Orbitrap showing drug load profiles (left panels) and native IM-MS plots of m/z vs. drift time from the Q-TOF instrument for brentuximab vedotin (a), trastuzumab emtansine (b) and CBW-03–106 DAR4 site-specific ADC (c).